Therapies that are believed to target the underlying mechanisms of Alzheimers disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimers disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimers disease. In the review, the current status of Alzheimers Disease therapies under study is discussed, including the scientific basis for each strategy.
Alzheimer's disease, clincal trials, drug development for Alzheimer's disease, mild cognitive impairment
Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego 9500 GilmanDrive ε La Jolla, California 92093, USA.